Trials / Terminated
TerminatedNCT02125617
Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer
uPAR in Blood From Zytiga® (Abiraterone) Treated Patients With Castration Resistant Prostate Cancer - a Predictive Marker of Response?
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 3 (actual)
- Sponsor
- Kristoffer Rohrberg · Academic / Other
- Sex
- Male
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate cleavage products of the urokinase plasminogenactivator receptor (uPAR) in plasma from patients with castration resistant prostate cancer as a predictive marker of response to abiraterone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abiraterone | 1000 mg/day |
| DRUG | Prednisolone | 10 mg/day |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2016-07-15
- Completion
- 2017-02-14
- First posted
- 2014-04-29
- Last updated
- 2026-01-14
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02125617. Inclusion in this directory is not an endorsement.